Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
PULMthis companyPulmatrix, Inc.	$1.39	-1.58×	2.14×	0×	-0.79×	-24.7%	0.0%	0.0%	0.0%	-135.5%	-135.7%	-66.7%	0×	0.79×	0×	12.55×	0.0%	1	-130.04	2	C
ASBPAspire Biopharma Holdings, Inc.	$8.03	-9.67×	-37.14×	38,181.4×	-20.93×	-107.4%	-1.9%	-312016.9%	-394725.1%	383.9%	395.3%	-2.1%	-0.22×	-0.03×	-2.27×	0.17×	0.0%	5	-3.49	2	C
CRISCuris, Inc.	$0.75	-1.7×	2.38×	1.38×	-1.83×	-1429.1%	99.5%	-348.4%	-80.3%	-138.8%	-464.7%	-209.4%	0.3×	0.66×	-15.06×	0.49×	0.0%	0	-98.45	1	C-
CTXRCitius Pharmaceuticals, Inc.	$0.55	-0.37×	0.2×	0×	-0.3×	64.2%	0.0%	0.0%	0.0%	-55.4%	-44.2%	-193.5%	0.03×	0.06×	-143.87×	0.62×	0.0%	3	-4.03	2	B-
DAREDare Bioscience, Inc.	$0.65	-1.61×	75.9×	209.43×	-18.58×	-72.9%	-137.5%	-1315.5%	-1300.7%	-471.4%	-124.5%	-4.8%	0.93×	2.12×	-16.47×	1.14×	0.0%	2	-13.47	2	C+
FBLGFibroBiologics, Inc. Common Stock	$0.99	-0.54×	1.63×	0×	-0.43×	-21.2%	0.0%	0.0%	0.0%	-302.9%	-194.4%	-165.8%	0.39×	0.14×	-81.61×	3.61×	0.0%	2	-16.92	2	B-
Peer median	—	-1.61×	1.63×	1.38×	-1.83×	-72.9%	0.0%	-348.4%	-80.3%	-138.8%	-124.5%	-165.8%	0.3×	0.14×	-16.47×	0.62×	0.0%	2	-13.47	2	—